Compare Bristol-Myers Squibb Co (BMY) vs Fox Corp Class B (FOX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Fox Corp Class B — how do they compare? Bristol-Myers Squibb Co trades at $58.39 (market cap $116.30B), while Fox Corp Class B trades at $50.28 (market cap $21.85B). The key difference: Bristol-Myers Squibb Co is far larger — about 5.3× Fox Corp Class B's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | FOX | |
|---|---|---|
Market Cap | $116.30B | $21.85B |
Sector | Health | Media |
52-Week High | $62.37 | $67.76 |
52-Week Low | $42.60 | $44.39 |
Enterprise Value | $152.24B | $25.83B |
Dividend Yield | 4.42% | 1.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
FOX trades at $50.22, up 3.02% with bullish technical signals and strong earnings beats. Recent Q1 2026 EPS of $1.32 exceeded expectations by 33.6%, continuing a pattern of outperformance. The company shows improved cash flow with 2025 operating cash flow reaching $3.32 billion, while revenue grew to $16.30 billion. Technical indicators show mixed signals with RSI at neutral levels but ADX suggesting strong trend momentum.
The outlook remains positive with analyst price targets suggesting 27-39% upside potential. Key risks include competitive pressures in streaming and potential volatility from the recent Roku acquisition. Wall Street sentiment is cautiously optimistic with 43% buy ratings, though the stock faces near-term execution challenges with projected 2026 cash flow turning negative.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →
